Galapagos NV (LON:0JXZ)

Market Cap	1.63B +32.9%
Revenue (ttm)	250.44M +10.3%
Net Income	-380.53M
EPS	-5.78
Shares Out	n/a
PE Ratio	n/a
Forward PE	13.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	841
Average Volume	2,930
Open	28.10
Previous Close	28.40
Day's Range	28.24 - 28.54
52-Week Range	19.99 - 32.70
Beta	0.10
RSI	50.94
Earnings Date	Feb 23, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 558
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JXZ

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial numbers in EUR